医学と薬学　77/8　2020年8月号

出版社： 自然科学社
発行日： 2020-07-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 白斑
電子書籍版： 2020-07-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　白斑

    序文
    白斑の診療ガイドライン―世界と日本
    白斑の病因論―2020
    白斑の診断と鑑別診断―小児例と成人例
    白斑の治療アップデート
    免疫チェックポイント阻害薬と白斑
    白斑と再生医療
    　―iPS細胞からの色素細胞前駆細胞の誘導
    白斑研究の新たな視点

    Diagnosis
    　光導波路伝搬光の減衰を増幅して抗原の検出を行う
    　　RSウイルス抗原検出迅速診断キット
    　安定心不全患者におけるNT-proBNP濃度の変動と心臓血管事故の関係
    　肝および造血幹細胞移植症例における
    　　サイトメガロウイルスモニタリングにおけるPCR法の有用性
    　尿中有形成分分析装置3機種の比較検討
    　化学発光酵素免疫測定法を用いた
    　　高感度新型コロナウイルスSARS-CoV-2抗原測定試薬の開発

    Health Care
    　植物ポリフェノール混合原料「DVAN8876」を配合した
    　　頭皮用化粧品の養育毛作用

    Cosmetic
    　加水分解バオバブエキス配合の男性の
    　　顔用ミスト状ローションのたるみ改善効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 白斑】

P.1119 掲載の参考文献
1) Drake LA, Dinehart SM, Farmer ER, et al : Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol 35 : 620-626, 1996.
PubMed
2) Gawkrodger DJ, Ormerod AD, Shaw L, et al : Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159 : 1051-1076, 2008.
PubMed
3) Taieb A, Alomar A, Bohm M, et al : Guidelines for the management of vitiligo : the European Dermatology Forum consensus. Br J Dermatol 168 : 5-19, 2013.
PubMed
4) 鈴木民夫, 金田眞理, 種村篤, 他 : 日本皮膚科学会ガイドライン, 尋常性白斑診療ガイドライン. 日皮会誌 122 (7) : 1725-1740, 2012.
 
5) Oiso N, Suzuki T, Wataya-Kaneda M et al : Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol 40 : 344-354, 2013.
PubMed
6) Mohammad TF, Al-Jamal M, Hamzavi IH, et al : The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol 76 : 879-888, 2017.
 
7) Ezzedine K, Lim HW, Suzuki T, et al : Revised classification/nomenclature of vitiligo and related issues : the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25 : E1-13, 2012.
PubMed
8) Drake LA, Ceilley RI, Dorner W, et al : Guidelines of care for phototherapy and photochemotherapy. American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol 31 : 643-648, 1994.
 
9) Taieb A, Picardo M : Epidemiology, definitions and classification. Vitiligo (ed. by Picardo M, Taieb A), pp.13-24, Springer Verlag, Heidelberg, 2010.
 
10) Eleftheriadou V, Thomas K, Geel N, et al : Developing core outcome set for vitiligo clinical trials : international e-Delphi consensus. Pigment Cell Melanoma Res 28 : 363-369, 2015.
PubMed
11) Gan E, Eleftheriadou V, Samia Esmat S, et al : Repigmentation in vitiligo : position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 30 : 28-40, 2017.
 
12) Nanja van Geel N, Wolkerstorfer A, Ezzedine K, et al : Validation of a physician global assessment tool for vitiligo extent : Results of an international vitiligo expert meeting Pigment Cell Melanoma Res 32 : 728-733, 2019.
 
13) Attili VR, Attili SK : Lichenoid inflammation in vitiligo-A clinical and histopathologic review of 210 cases. Int J Dermatol 47 : 663-669, 2008.
PubMed
P.1125 掲載の参考文献
1) Ezzedine K, Lim HW, Suzuki T et al : Revised classification/nomenclature of vitiligo and related issues : the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25 (3) : E1-13, 2012.
PubMed
2) Kotobuki Y, Tanemura A, Yang L et al : Dysregulation of melanocyte function by Th17-related cytokines : significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res 25 : 219-230, 2012.
PubMed
3) Hueber AJ, Asquith DL, Miller AM et al : Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184 (7) : 3336-3340, 2010.
PubMed
4) Wagner RY, Luciani F, Cario-Andre M et al : Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol 135 : 1810-1819, 2015.
PubMed
5) Yoshida M, Takahashi Y, Inoue S : Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H2 receptors in human normal melanocytes. J Invest Dermatol. 114 (2) : 334-342, 2000.
PubMed
6) Yamaguchi Y, Hearing VJ : Physiological factors that regulate skin pigmentation. Biofactors 35 (2) : 193-199, 2009.
PubMed
7) Cho KA, Park M, Kim YH et al : Th17 cell-mediated immune responses promote mast cell proliferation by triggering stem cell factor inkeratinocytes. Biochem Biophys Res Com 487 (4) : 856-861, 2017.
PubMed
8) Zhou J, An X, Dong J et al : IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo. FASEB J 32 (9) : 4899-4916, 2018.
 
9) Li S, Zhu G, Yang Y et al : Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. J Allergy Clin Immunol 140 : 177-189, 2017.
 
10) Speeckaert R, Voet S, Hoste E et al : S100B Is a potential disease activity marker in non- segmental vitiligo. J Invest Dermatol 137 : 1445-1453, 2017.
 
11) Mishima Y, Kawasaki H, Pinkus H : Dendritic cell dynamics in progressive depigmentations. Distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch 243 (2) : 67-87, 1972.
PubMed
12) Breathnach AS : A new concept of the relation between the Langerhans cell and the melanocyte. J Invest Dermatol 40 : 279-281, 1963.
PubMed
13) Koch S, Stroisch TJ, Vorac J et al : AhR mediates an anti-inflammatory feedback mechanism in human Langerhans cells involving Fc ε RI and IDO. Allergy 72 (11) : 1686-1693, 2017.
 
14) Nguyen NT, Kimura A, Nakahama T et al : Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 107 (46) : 19961-19966, 2010.
 
15) Wagner RY, Luciani F, Cario-Andre M et al : Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol 135 : 1810-1819, 2015.
PubMed
16) Kazal B, Takahashi A, Mizutani Y et al : Glycoprotein Non-metastatic B (GPNMB)/Osteoactivin is expressed in human epidermal keratinocytes, but disappeared in the vitiligo lesional skin. (投稿中)
 
17) Kovacs D, Bastonini E, Ottaviani M et al : Vitiligo Skin : Exploring the Dermal Compartment. J Invest Dermatol 138 : 394-404, 2018.
PubMed
18) Rothstein B, Joshipura D, Saraiya A et al : Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76 : 1054-1060, 2017.
PubMed
19) Hosking AM, Juhasz M, Mesinkovska NA : Topical Janus kinase inhibitors : A review of applications in dermatology. J Am Acad Dermatol 79 (3) : 535-544, 2018.
PubMed
20) Bhardwaj S, Bhatia A, Kumaran MS et al : Role of IL-17A receptor blocking in melanocyte survival : A strategic intervention against vitiligo. Exp Dermatol 28 (6) : 682-689, 2019.
PubMed
21) Speeckaert R, Mylle S, van Geel N : IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res 32 (6) : 842-847, 2019.
PubMed
P.1131 掲載の参考文献
1) Ezzedine K, Lim HW, Suzuki T et al : Revised classification/nomenclature of vitiligo and related issues : the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25 (3) : E1-E13, 2012.
PubMed
2) 鈴木民夫, 金田眞理, 種村篤他 : 尋常性白斑診療ガイドライン. 日皮会誌 122 (7) : 1725-1740, 2012.
 
3) Oiso N, Suzuki T, Wataya-Kaneda M et al : Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol 40 (5) : 344-354, 2013.
PubMed
4) Rodrigues M, Ezzedine K, Hamzavi I et al : New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77 (1) : 1-13, 2017.
PubMed
5) Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin 35 (2) : 245-255, 2017.
PubMed
6) Narita T, Oiso N, Fukai K et al : Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int 60 (4) : 505-508, 2011.
PubMed
7) Taieb A, Seneschal J, Mazereeuw-Hautier J : Special considerations in children with vitiligo. Dermatol Clin 35 (2) : 229-233, 2017.
PubMed
8) Ezzedine K, Le Thuaut A, Jouary T et al : Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res 27 (1) : 134-139, 2014.
PubMed
9) Dahir AM, Thomsen SF. Comorbidities in vitiligo : comprehensive review. Int J Dermatol 57 (10) : 1157-1164, 2018.
PubMed
10) Aboul-Fettouh N, Hinojosa J, Tovar-Garza A et al : The majority of patients presenting with vitiligo have a clinical sign of activity. J Am Acad Dermatol 77 (4) : 774-775, 2017.
PubMed
11) van Geel N, Speeckaert R : Segmental Vitiligo. Dermatol Clin 35 (2) : 145-150, 2017.
PubMed
12) Oiso N, Kawada A : Superimposed segmental vitiligo (mixed vitiligo) with non-segmental vitiligo and segmental vitiligo along the narrow Blaschko lines (type 1a). J Dermatol 43 (11) : 1388-1389, 2016.
PubMed
13) Grill C, Benzekri L, Rubod A et al : Epidermal melanocytes in segmental vitiligo show altered expression of E-cadherin, but not P-cadherin. Br J Dermatol 178 (5) : 1204-1206, 2018.
 
14) 大磯直毅 : 脱色素性母斑, 伊藤白斑. 小児科診療 78 (11) : 1555-1558, 2015.
Medical*Online
15) Arase N, Tanemura A, Jin H et al : Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma. J Dermatol Sci 95 (2) : 80-83, 2019.
 
16) Goto N, Tsujimoto M, Nagai H et al : 4- (4-Hydroxyphenyl) -2-butanol (rhododendrol) -induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress. Exp Dermatol 27 (7) : 754-762, 2018.
PubMed
P.1140 掲載の参考文献
1) Clayton R : A double blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol 96 : 71-73, 1977.
 
2) 鈴木民夫, 金田眞理, 種村篤他 : 日本皮膚科学会ガイドライン, 尋常性白斑診療ガイドライン. 122 : 1725-1740, 2012.
 
3) 加藤則人, 大矢幸弘, 池田政憲, 他 : 日本皮膚科学会ガイドライン, アトピー性皮膚炎診療ガイドライン 2018. 日皮会誌 128 (12) : 2431-2502, 2018.
 
4) Watabe H, Soma Y, Kawa Y, et al : Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 119 : 583-589, 2002.
PubMed
5) Kawakami T, Ohgushi A, Hirobe T, et al : Effects of 1,25-dihydroxyvitamin D3 on human epidermal melanocytes and melanoblasts. J Dermatol Sci 76 : 72-74, 2014.
PubMed
6) Yamanaka KI, Kakeda M, Kitagawa H, et al : 1,24-Dihydroxyvitamin D (tacalcitol) prevents skin T-cell infiltration. Br J Dermatol 162 : 1206-1215, 2010.
PubMed
7) Ameen M, Exarchou V, Chu AC : Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 145 (3) : 476-479, 2001.
PubMed
8) Chiaverini C, Passeron T, Ortonne JP : Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 16 : 137-138, 2002.
PubMed
9) Khullar G, Kanwar AJ, Singh S, et al : Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo : a 24-week prospective right-left comparative clinical trial. J Eur Acad Dermatol Venereol 29 (5) : 925-932, 2015.
PubMed
10) Lan CC, Chen GS, Chiou MH, et al : FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes : possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153 (3) : 98-505, 2005.
 
11) Jung H, Chung H, Chang SE, et al : FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. Pigment Cell Melanoma Res 29 (2) : 199-209, 2016.
PubMed
12) Arora CJ, Rafiq M, Shumack S, et al : The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo : A systematic review of randomised clinical trials. Australas J Dermatol 61 (1) : e1-e9, 2020.
PubMed
13) Taieb A, Alomar A, Bohm M et al : Guidelines for the management of vitiligo : the European Dermatology Forum consensus. Br J Dermatol 168 (1) : 5-19, 2013.
PubMed
14) 種村篤 : 色素脱失・白斑-実臨床に沿った尋常性白斑の診療-. Skin Surgery 25 : 127-138. 2016.
Medical*Online
15) Harris JE, Harris TH, Weninger W, et al : A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 132 (7) : 1869-1876, 2012.
 
16) Craiglow BG, King BA : Tofacitinib Citrate for the Treatment of Vitiligo : A Pathogenesis-Directed Therapy. JAMA Dermatol 151 (10) : 1110-1112, 2015.
PubMed
17) Hayashi M, Okamura K, Abe Y, et al. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo. J Dermatol 46 (6) : 548-550, 2019.
 
18) Harris JE, Rashighi M, Nguyen N, et al : Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74 (2) : 370-371, 2016.
 
19) Liu LY, Strassner JP, Refat MA, et al : Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77 (4) : 675-682, 2017.
PubMed
20) Joshipura D, Alomran A, Zancanaro P, et al : Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib : A 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 78 (6) : 1205-1207, 2018.
 
21) Strassner JP, Harris JE : Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol 43 : 81-88, 2016.
PubMed
22) Kato H, Furuhashi T, Ito E, et al : Efficacy of 1-mm minigrafts in treating vitiligo depends on patient age, disease site and vitiligo subtype. J Dermatol 38 (12) : 1140-1145, 2011.
PubMed
23) Sheth VM, Currimbhoy SD, Feetham HJ, et al : Efficacy of narrowband ultraviolet B versus excimer radiation in repigmenting vitiligo after minigrafting on the distal arms. J Am Acad Dermatol 67 (2) : 318-320, 2012.
 
24) Mapar MA, Safarpour M, Mapar M, et al : A comparative study of the mini-punch grafting and hair follicle transplantation in the treatment of refractory and stable vitiligo. J Am Acad Dermatol 70 (4) : 743-747, 2014.
PubMed
25) Kovacs D, Abdel-Raouf H, Al-Khayyat M, et al : Vitiligo : characterization of melanocytes in repigmented skin after punch grafting. J Eur Acad Dermatol Venereol 29 (3) : 581-590, 2015.
PubMed
26) Abdallah M, Abdel-Naser MB, Moussa MH, et al : Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. Eur J Dermatol 13 (6) : 548-552, 2003.
PubMed
27) Ezz-Eldawla R, Abu El-Hamd M, Saied SM, et al : A comparative study between suction blistering graft, mini punch graft, and hair follicle transplant in treatment of patients with stable vitiligo. J Dermatolog Treat 30 (5) : 492-497, 2019.
 
28) Rao A, Gupta S, Dinda AK, et al. Study of clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo undergoing melanocyte transplantation. Br J Dermatol 166 (6) : 1230-1236, 2012.
PubMed
29) Mohanty S, Kumar A, Dhawan J, et al : Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo. Br J Dermatol 164 (6) : 1241-1246, 2011.
 
30) Guerra L, Primavera G, Raskovic D, et al : Erbium : YAG laser and cultured epidermis in the surgical therapy of stable vitiligo. Arch Dermatol 139 (10) : 1303-1310, 2003.
PubMed
31) Tanioka M, Yamamoto Y, Kato M, et al : Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol 9 (1) : 72-75, 2010.
PubMed
32) 加藤裕史, 森田明理 : 尋常性白斑の外科的治療. Derma 171 : 27-32, 2010.
Medical*Online
33) Richmond JM, Strassner JP, Zapata L Jr, et al : Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med 10 (450), 2018. doi : 10.1126/scitranslmed.aam7710
 
P.1149 掲載の参考文献
1) Lerner AB : On the etiology of vitiligo and grey hair. Am J Med 51 : 141-147, 1971.
PubMed
2) Howitz J, Brodthagen H, Schwartz M, et al : Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 113 : 47-52, 1977.
PubMed
3) GLOBOCAN : Cancer Incidence, Mortality and Prevalence Worldwide. Lyon : World Health Organization, 2001.
 
4) Chapman PB, Einhorn LH, Meyers ML, et al : Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 (9) : 2745-2751, 1999.
PubMed
5) Hodi FS, O'Day SJ, McDermott DF, et al : Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (8) : 711-723, 2010.
PubMed
6) Postow MA, Harding J, Wolchok JD, et al : Targeting immune checkpoints : releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 18 (2) : 153-159, 2012.
PubMed
7) Pardoll DM : The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (4) : 252-264, 2012.
PubMed
8) Snyder A, Makarov V, Merghoub T, et al : Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (23) : 2189-2199, 2014.
PubMed
9) Topalian SL, Sznol M, McDermott DF, et al : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (10) : 1020-1030, 2014.
PubMed
10) Weber JS, D'Angelo SP, Minor D, et al : Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037) : a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (4) : 375-384, 2015.
PubMed
11) Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al : Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377 (14) : 1345-1356, 2017.
PubMed
12) Das R, Verma R, Sznol M, et al : Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194 (3) : 950-959, 2015.
PubMed
13) Freeman-Keller M, Kim Y, Cronin H, et al : Nivolumab in resected and unresectable metastatic melanoma : characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22 (4) : 886-894, 2016.
PubMed
14) Teulings HE, Limpens J, Jansen SN, et al : Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival : a systematic review and meta-analysis. J Clin Oncol 33 (7) : 773-781, 2015.
PubMed
15) Sibaud V, Meyer N, Lamant L, et al : Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28 (4) : 254-263, 2016.
PubMed
16) Nakamura Y, Tanaka R, Asami Y, et al : Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab : a multi-institutional retrospective study. J Dermatol 44 (2) : 117-122, 2017.
PubMed
17) Larsabal M. Marti A, Jacquemin C, et al : Vtiligo-like occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76 : 863-870, 2017.
 
18) Boniface K, Dutriaux C, Prey S, et al : Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol 78 (1) : e17-e18, 2018.
PubMed
19) Fukuda K, Harris JE : Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo. J Am Acad Dermatol 78 (1) : e15-e16, 2018.
PubMed
20) Nishino K, Ohe S, Kitamura M, et al : Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung. J Thoracic Dis 10 (6) : E481-E484, 2018.
 
21) Uenami T, Hosono Y, Ishijima M, et al : Vitiligo in a patient with lung adenocarcinoma treated with nivolumab : a case report. Lung Cancer 109 : 42-44, 2017.
 
22) Yin ES, Totonchy MB, Leventhal JS : Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia : a novel finding. JAAD Case Rep 3 (2) : 90-92, 2017.
 
P.1158 掲載の参考文献
1) Hosaka C, Kunisada M, Koyanagi-Aoi M, et al : Induced pluripotent stem cell-derived melanocyte precursor cells undergoing differentiation into melanocytes. Pigment Cell Melanoma Res 32 (5) : 623-633, 2019.
PubMed
2) Ohta S, Imaizumi Y, Okada Y, et al : Generation of human melanocytes from induced pluripotent stem cells. PLoS One 6 (1) : e16182, 2011.
PubMed
3) Mica Y, Lee G, Chambers SM, et al : Modeling neural crest induction, melanocyte specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs. Cell Rep 3 (4) : 1140-1152, 2013.
PubMed
4) Mackenzie MA, Jordan SA, Budd PS, et al : Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo, Dev Biol 192 (1) : 99-107, 1997.
PubMed
5) Nishimura EK, Jordan SA, Oshima H, et al : Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416 (6883) : 854-860, 2002.
PubMed
6) Nishimura EK, Suzuki M, Igras V, et al : Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell stem cell 6 (2) : 130-140, 2010.
PubMed
7) Pino D, Choe Y, Pleasure SJ : Pleasure, Wnt5a controls neurite development in olfactory bulb interneurons. ASN neuro 3 (3) : e00059, 2011.
PubMed
8) Fujiwara S, Nagai H, Jimbo H, et al : Gene Expression and Methylation Analysis in Melanomas and Melanocytes From the Same Patient : Loss of NPM2 Expression Is a Potential Immunohistochemical Marker for Melanoma, Front Oncol 8 : 675, 2018.
PubMed
P.1165 掲載の参考文献
1) Wagner RY, Luciani F, Cario-Andre M, et al : Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol 135 : 1810-1819, 2015.
PubMed
2) Strassner JP, Rashighi M, Ahmed Refat M, et al : Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol 76 : 847-855 e5, 2017.
 
3) Sahoo A, Lee B, Boniface K, et al : MicroRNA-211 regulates oxidative phosphorylation and energy metabolism in human vitiligo. J Invest Dermatol 137 : 1965-1974, 2017.
PubMed
4) Mathieu M, Martin-Jaular L, Lavieu G, et al : Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21 : 9-17, 2019.
PubMed
5) Colombo M, Raposo G, Thery C : Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30 : 255-289, 2014.
PubMed
6) Raposo G, Stoorvogel W : Extracellular vesicles : exosomes, microvesicles, and friends. J Cell Biol 200 : 373-383, 2013.
 
7) Lo Cicero A, Delevoye C, Gilles-Marsens F, et al : Exosomes released by keratinocytes modulate melanocyte pigmentation. Nat Commun 6 : 7506, 2015.
 
8) Kim NH, Choi SH, Kim CH, et al : Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target. J Invest Dermatol 134 : 1075-1082, 2014.
PubMed

【Diagnosis】

P.1173 掲載の参考文献
1) 国立感染症研究所感染症発生動向調査. 週報グラフ, RSウイルス感染症 https://www.niid.go.jp/niid/ja/10/2096-weeklygraph/1661-21rsv.html
 
2) 堤裕幸 : RSウイルス感染症. 感染症誌 79 : 857-863, 2005.
 
3) 河合直樹, 池松秀之, 岩城紀男, 他 : PCRによる高齢者を含めたRSウイルス検出例の検討-新しい迅速診断キットの試用経験を含めて-. 感染症誌 82 : 1-5, 2008.
 
4) イムノエース(R) RSV Neo 添付文書. 2018年7月改訂 (第7版) http://imunoace.jp/pdf/rsv/imunoace_rsvneo_packageinsert_c71.pdf
 
5) クイック チェイサー(R) RSV添付文書. 2015年10月改訂 (第9版) https://www.mizuho-m.co.jp/product/uploads/attach/11_QC_RSV_01.pdf
 
6) 国立感染症研究所病原体検出マニュアル : ヒトオルソニューモウイルス (RSウイルス) 病原体検出マニュアル 2.0版 令和2年6月12日 https://www.niid.go.jp/niid/images/lab-manual/RSVirus20200612.pdf
 
7) 大宮卓, 久保亨, 西村秀一 : イムノクロマト法を原理とする12種のRSウイルス迅速抗原検出キット製品のウイルス検出の感度性能の比較. 感染症誌 90 : 633-638, 2016.
 
8) P R Johnson, M K Spriggs, R A Olmsted, P L Collins : The G glycoprotein of human respiratory syncytial viruses of subgroups A and B : extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci 84 (16) : 5625-5629, 1987.
 
9) Peret TC, Hall CB, Schnabel KC, et al : Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 79 (Pt 9) : 2221-2229, 1998.
 
10) Kuroiwa Y, Nagai K, Okita L, et al : A phylogenetic study of human respiratory syncytial viruses group A and B strains isolated in two cities in Japan from 1980-2002. J Med Virol 76 : 241-247, 2005.
 
11) 齋藤玲子, 齋藤孔良, Isolde Caperig Dapat, et al : わが国のRSVの分子疫学. IASR 35 (6) : 148-149, 2014.
 
P.1179 掲載の参考文献
1) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart ssociation Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23 (8) : 628-651, 2017.
 
2) 慢性心不全治療ガイドライン (2018年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2017tsutsui_h.pdf.
 
3) Tsutamoto T, et al : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 : 509-516, 1997.
PubMed
4) 蔦本尚慶, 斉藤能彦 : 新BNPと日常診療-心機能異常の早期発見のために. 南江堂, 東京, 2005.
 
5) Januzzi JL, et al : NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure : an international pooled analysis of 1256 patients : the International Collaborative of NT-proBNP Study. Eur Heart J 27 (3) : 330-337, 2006.
 
6) Maeda K, et al : Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 : 825-832, 1998.
PubMed
7) Nishiyama K, et al : Relationship between biological variation in B-type natriuretic peptide and plasma renin concentration in stable outpatients with dilated cardiomyopathy. Circ J 75 (8) : 1897-1904, 2011.
 
8) Nishiyama K, et al : Biological variation of brain natriuretic peptide and cardiac events in stable outpatients with nonischemic chronic heart failure. Circ J 75 (2) : 341-347, 2011.
PubMed
9) Tsutamoto T, et al : Direct Comparison of Transcardiac Difference Between Brain Natriuretic Peptide (BNP) and N-terminal pro-BNP in Patients With Chronic Heart Failure. Eur J Heart Fail 9 (6-7) : 667-673, 2007.
 
10) 蔦本尚慶 : 心不全バイオマーカーとしてのナトリウム利尿ペプチドの歴史と展望. 医学と薬学 76 (10) : 1457-1473, 2019.
Medical*Online
11) Sakai H, et al : Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J 71 (4) : 499-505, 2007.
 
12) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (11) : 993-1004, 2014.
PubMed
13) Packer M, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (8) : 920-926, 2002.
PubMed
14) Ibrahim NE, et al : Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol 73 (11) : 1273-1284, 2019.
PubMed
15) Packer M, et al : Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (1) : 54-61, 2015.
PubMed
P.1187 掲載の参考文献
1) 小杉伊三夫 : サイトメガロウイルス (CMV). ウイルス 60 (2) : 209-220, 2010.
 
2) 日本造血細胞移植学会 : 造血細胞移植ガイドラインウイルス感染症の予防と治療 サイトメガロウイルス感染症 (第4版)
 
3) 一般社団法人日本臨床腎移植学会 : 腎移植後サイトメガロウィルス感染症の診療ガイドライン 2011.
 
4) Morinaga Y, Sawayama Y, Hidaka M, et al : Diagnostic Utility of Cytomegalovirus Nucleic Acid Testing during Antigenemia-Guided Cytomegalovirus Monitoring after Hematopoietic Stem Cell Transplantation or Liver Transplantation. Tohoku J Exp Med 247 (3) : 179-187, 2019.
PubMed
5) Kotton CN, Kumar D, Caliendo AM, et al. The Transplantation Society International CMV Consensus Group. The ThirdInternational Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 102 : 900-931, 2018.
 
6) Martin-Gandul C, Perez-Romero P, Sanchez M, et al : Spanish Network for Research in Infectious Diseases. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 56 : 13-18, 2013.
 
7) Griffiths PD, Rothwell E, Raza M, et al : Correction : Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS One 12 (9) : e0185298,2017.
PubMed
8) Dioverti MV, Lahr BD, Germer JJ et al : Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease. Open Forum Infect Dis 4 (3) : ofx143, 2017.
PubMed
P.1200 掲載の参考文献
1) 日本臨床衛生検査技師会 : 尿沈渣検査法 2010, 日本臨床検査技師会編, 2011.
 
2) 田中佳 : 各種尿中有形成分分析装置の特徴と運用方法. 検査と技術 46 (2) : 152-157, 2018.
 
3) 舛岡正二郎 : 全自動尿中有形成分分析装置「U-SCANNER II」. 生物試料分析 30 (4) : 309-312, 2007.
Medical*Online
4) 堀田真希, 小林渉, 松田沙希子, 他 : 尿中有形成分分析装置Atellica UAS800の基礎的検討. 医学と薬学 75 (4) : 407-415, 2018.
Medical*Online
5) 橋本綾, 田中佳, 松本正美, 他 : 全自動尿中有形成分分析装置UF-5000の性能評価. 医学検査 66 (3) : 255-265, 2017.
Medical*Online
6) 久枝恵美子, 緒方清香, 今井郁子, 他 : 尿中有形成分分析装置三機種の比較および性能評価. 日本臨床検査自動化学会会誌 33 (5) : 833-839, 2008.
 
P.1208 掲載の参考文献
1) Wu Z, McGoogan J : Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA 323 (13) : 1239-1242, 2020.
PubMed
2) WHO : Coronavirus disease (COVID-19) Situation Report- 154 : 22, 2020.
 
3) Gorbalenya A, Baker S, Baric R, et al : The species Severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5 : 536-544, 2020.
PubMed
4) 診療の手引き検討委員会・作成班 : 新型コロナウイルス感染症 (COVID-19) 診療の手引き・第2版 : 2020年5月18日.
 
5) 山川賢太郎, 藤本陽, 宮本和慶, 他 : イムノクロマト法を用いた新型コロナウイルスSARS-CoV-2抗原検出試薬の開発. 医学と薬学 77 (6) : 937-944, 2020.
Medical*Online
6) Nishizono I, Iida S, Suzuki N, et al : Rapid and Sensitive Chemiluminescent Enzyme Immunoassay for Measuring Tumor Markers. Clin Chem 37 : 1639-1644, 1991.
PubMed
7) Patterson E, Prince T, Anderson E, et al : Methods of inactivation of SARS-CoV-2 for downstream biological assays. bioRxiv, 2020. https://dx.doi.org/10.1101/2020.05.21.108035
 
8) Pastorino B, Touret F, Gilles M, et al : Evaluation of heating and chemical protocols for inactivating SARS-CoV-2. bioRxiv, 2020. https://dx.doi.org/10.1101/2020.04.11.036855
 
9) Pan Y, Long L, Zhang D, et al : Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads. Clinical chemistry 66 (6) : 794-801, 2020.
 
10) Chen H, Wu R, Xing Y, et al : Influence of Different Inactivation Methods on Severe Acute Respiratory Syndrome Coronavirus 2 RNA Copy Number. Journal of Clinical Microbiology, 2020. https://dx.doi.org/10.1128/jcm.00958-20
 
11) Hu X, An T, Situ B, et al : Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2. medRxiv, 2020. https://dx.doi.org/10.1101/2020.03.12.20034231
 
12) Darnell M, Subbarao K, Feinstone S, et al : Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. Journal of Virological Methods 121 (1) : 85-91, 2004.
PubMed

【Health Care】

P.1217 掲載の参考文献
1) 株式会社リクルートライフスタイル ホットペッパービューティーアカデミー. 2019年薄毛調査報告書
 
2) 眞鍋求, 坪井良治, 板見智, 他 : 男性型および女性型脱毛症診療ガイドライン 2017年版. 日本皮膚科学会雑誌 127 (13) : 2763-2777, 2017.
 
3) 江浜律子, 岩渕徳郎, 飯野雅人, 他 : 女性の薄毛とアデノシンによる改善効果. 日本化粧品技術者会誌 45 (1) : 35-40, 2011.
 
4) 岩渕徳郎 : 育毛薬剤の開発と評価方法 (これまでと今後). 日本香粧品学会誌 42 (1) : 98-103, 2018.
 
5) 小野佳子 : ポリフェノールの機能解明に関する研究とその応用開発. 化学と生物 57 (9) : 525-531, 2019.
 
6) Kim BJ, Kim MH, Oh JK, et al : Objective evaluation of photoepilation by phototrichogram. J Dermatol 37 (12) : 1019-24, 2010.
PubMed
7) 山本將 : ヒト頭毛の成長-研究法, 頭毛の種類, 成長速度-. 山野研究紀要 12 : 95-102, 2004.
 
8) 鈴木啓子, 中野ひとみ : 香草類ポリフェノールの機能性. 日本調理科学会大会研究発表要旨集 29 : 163, 2017.
 
9) 立山千草, 本間伸夫, 並木和子, 他 : 食用花弁に含まれるポリフェノール類含有量と抗酸化活性. 日本食品科学工学会誌 44 (4) : 290-299, 1997.
 
10) Hannum SM : Potential impact of strawberries on human health : a review of the science. Crit Rev Food Sci Nutr 44 (1) : 1-17, 2004.
 
11) Galati EM, Monforte MT, Kirjavainen S, et al : Biological effects of hesperidin, a citrus flavonoid. (Note I) : antiinflammatory and analgesic activity. Farmaco 40 (11) : 709-712, 1994.
 

【Cosmetic】

P.1222 掲載の参考文献
1) P Moussou, et al : Speci'men-The first natural agent made specifically for men's skin enabling healthy, more toned skin nor men. Household Personal Care 11 (2) : 2016.
 
2) T Milner-Krawczyk, M Pasikowska-Piwko, M et al : The Effect of Anti-aging Peptides on Mechanical and Biological Properties of HaCaT Keratinocytes. Int J Pept Res Ther 24 : 577-5870 2018.
 
3) Pascale Prouheze, et al : Preserving Hyalurosome to Limit Psychological Stress-Induced Premature Aging. IFSCC 3 : 141-147, 2017.
 

書評

最近チェックした商品履歴

Loading...